Department for Science, Innovation & Technology

Questions from the Department for Science, Innovation & Technology:

341-360 of 511 results
Government Office for Life Sciences - Investment - Business environment How are decisions on investment and location of manufacturing facilities affected by the broader commercial environment and, in particular, price regulation and other cost control measures? Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - Investment - Business environment We would like to understand the impact of operational costs (such as energy or materials along the supply chain) on the decision to locate and/or increase investment activity in the UK. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - Investment - Business environment We would like to understand the extent to which capital allowance rules and the overall corporate tax burden affects investment decisions in the sector. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - Investment - Business environment We would like to understand the extent to which the planning system limits investment activity in the sector. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - NHS Innovation, Uptake and Access Evidence on whether the commercial environment has a material impact on launch prioritisation for new drugs. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - NHS Innovation, Uptake and Access We would like to understand the relationship between drug launch / supply of new drugs and the broader commercial environment, including price regulation and other cost control measures. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - NHS Innovation, Uptake and Access Detailed data on the price per QALY associated with each medicine and medical technology purchased by the NHS. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - NHS Innovation, Uptake and Access Detailed data on uptake and access of medicines and medical technologies at the level of each commissioning unit. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - NHS Innovation, Uptake and Access Detailed data on the dates of regulatory approval and cost-effectiveness appraisal of medicines and medical technologies. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - NHS Innovation, Uptake and Access Estimates of the benefit and impact of introducing new technologies and therapeutics to the NHS. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - NHS Innovation, Uptake and Access Reliable estimates of the relative productivity of the different factors in the health production function for the NHS. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - Clinical trials Evidence on the main barriers to conducting clinical trial activity. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - Clinical trials Evidence on the economic impact of clinical trials and cost. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - Genomics Estimates of the economic impact and contribution of genomic activities, including returns to R&D spending. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - Genomics Evidence of the potential impact of genomics on the productivity of the pharmaceutical sector. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - Genomics Evidence on the potential impact of genomics on new therapeutics and interventions. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - Healthcare Missions (Cancer, Ageing, Dementia, Mental Health, Respiratory Disease, Obesity, Vaccines, Addiction) Evidence on whether reductions in excess adiposity improve patient outcomes and prevent the incidence of developing secondary disease or multiple long-term conditions. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - Healthcare Missions (Cancer, Ageing, Dementia, Mental Health, Respiratory Disease, Obesity, Vaccines, Addiction) Estimates of the returns to R&D spending in these disease areas. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - Healthcare Missions (Cancer, Ageing, Dementia, Mental Health, Respiratory Disease, Obesity, Vaccines, Addiction) A usable forward look on new technologies (including medicines, devices, therapeutics, precision medicine tools and approaches to drug development) in development. Department for Science, Innovation & Technology, 2024
See details
Government Office for Life Sciences - Healthcare Missions (Cancer, Ageing, Dementia, Mental Health, Respiratory Disease, Obesity, Vaccines, Addiction) Evidence on the prevalence of long-term conditions associated with the disease areas covered by the healthcare missions (cancer, ageing, dementia, mental health, respiratory disease, obesity, addiction). Further, we would like to understand what links exist between these disease areas: whether there are mutual risk factors or whether any of these disease areas are a risk factor for another. Department for Science, Innovation & Technology, 2024
See details
  • 18